Looking For More Data: Lilly’s Arxxant Gets “Approvable” Letter

Lilly is hopeful that data from an ongoing study will avoid the need for an additional trial.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet